Physician profile
William David Denney
NPI 1760595615
$6,030.31
in general payments reported to CMS, 2019-2025
35 companies · $796 in 2025
The $796 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $426 · 2021: $323 · 2022: $510 · 2023: $1,540 · 2024: $1,177 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,513.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $936.76 | 2019-2025 | Leqvio |
| Janssen Pharmaceuticals, INC | $676.73 | 2019-2024 | Xarelto |
| Pfizer INC. | $557.45 | 2019-2025 | |
| 3b Medical, INC. | $520.87 | 2023 | Luna |
| Amgen INC. | $446.99 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $423.24 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $333.21 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $298.56 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.78 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $195.41 | 2024-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $189.67 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $169.25 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $128.02 | 2019-2024 | Farxiga |
| Abbott Laboratories | $123.55 | 2021-2025 | Jot Dx, Accent, Aveir |
| Kiniksa Pharmaceuticals International, Plc | $83.65 | 2024 | Arcalyst |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $82.02 | 2023 | Inpefa |
| Boston Scientific Corporation | $81.16 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Inari Medical, INC. | $63.67 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $57.37 | 2024-2025 | |
| Scpharmaceuticals INC. | $54.86 | 2024 | |
| Glaxosmithkline, LLC. | $49.96 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $49.87 | 2021-2022 | |
| Astellas Pharma US INC | $36.03 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $34.81 | 2025 | Amvuttra |
| Irhythm Technologies, INC. | $33.40 | 2021-2022 | |
| Edwards Lifesciences Corporation | $30.66 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Impulse Dynamics (USA) INC. | $26.68 | 2023 | Optimizer |
| Lantheus Medical Imaging, INC. | $22.51 | 2019 | |
| Cvrx, INC. | $21.37 | 2025 | Barostim Neo System |
| Inspire Medical Systems, INC. | $20.92 | 2024 | Inspire |
| Shockwave Medical, INC | $17.58 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $15.74 | 2024 | Telescope |
| Kowa Pharmaceuticals America, INC. | $13.11 | 2019 | |
| Allergan, INC. | $13.05 | 2020 | |
| Argon Medical Devices, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Denney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.